Related references
Note: Only part of the references are listed.Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database
Pierre-Marie Morice et al.
LANCET HAEMATOLOGY (2021)
Specific Toxicity of Maintenance Olaparib Versus Placebo in Advanced Malignancies: A Systematic Review and Meta-analysis
Angela Dalia Ricci et al.
ANTICANCER RESEARCH (2020)
Phase I and pharmacokinetic study of veliparib, a PARP inhibitor, and pegylated liposomal doxorubicin (PLD) in recurrent gynecologic cancer and triple negative breast cancer with long-term follow-up
Bhavana Pothuri et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2020)
Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study
Wassim Abida et al.
CLINICAL CANCER RESEARCH (2020)
Exploring the perspectives of healthcare professionals in delivering optimal oncology medication education
Allison Lively et al.
PLOS ONE (2020)
Metabolic Stability Assessment of New PARP Inhibitor Talazoparib Using Validated LC-MS/MS Methodology: In silico Metabolic Vulnerability and Toxicity Studies
Mohamed W. Attwa et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2020)
The kinase polypharmacology landscape of clinical PARP inhibitors
Albert A. Antolin et al.
SCIENTIFIC REPORTS (2020)
Delayed PARP-1 Inhibition Alleviates Post-stroke Inflammation in Male Versus Female Mice: Differences and Similarities
Jian Chen et al.
FRONTIERS IN CELLULAR NEUROSCIENCE (2020)
Olaparib for Metastatic Castration-Resistant Prostate Cancer
J. de Bono et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment
Jean-David Fumet et al.
BMC CANCER (2020)
Current Strategies and Novel Therapeutic Approaches for Metastatic Urothelial Carcinoma
Veronica Mollica et al.
CANCERS (2020)
Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration
Wassim Abida et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Pamiparib is a potent and selective PARP inhibitor with unique potential for the treatment of brain tumor
Yao Xiong et al.
NEOPLASIA (2020)
PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance
Maddison Rose et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2020)
Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial
J. K. Litton et al.
ANNALS OF ONCOLOGY (2020)
The role of the pharmacist in the multidisciplinary approach to the prevention and resolution of drug-related problems in cancer chemotherapy
Ahmet S. Bosnak et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2019)
NADP+ is an endogenous PARP inhibitor in DNA damage response and tumor suppression
Chunjing Bian et al.
NATURE COMMUNICATIONS (2019)
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
Talia Golan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Adult Cancer Pain, Version 3.2019
Robert A. Swarm et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2019)
Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial
Michael Friedlander et al.
LANCET ONCOLOGY (2019)
Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer
R. L. Coleman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
PARP-1 activity (PAR) determines the sensitivity of cervical cancer to olaparib
Anna Bianchi et al.
GYNECOLOGIC ONCOLOGY (2019)
Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed, BRCA-mutated, high-grade ovarian cancer, and an update on safety
Rebecca S. Kristeleit et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2019)
Real-world adverse events with niraparib 200 mg/day maintenance therapy in ovarian cancer: a retrospective study
Jack R. Gallagher et al.
FUTURE ONCOLOGY (2019)
PARP1 Trapping by PARP Inhibitors Drives Cytotoxicity in Both Cancer Cells and Healthy Bone Marrow
Todd A. Hopkins et al.
MOLECULAR CANCER RESEARCH (2019)
Oral Hygiene Care in Patients With Advanced Disease: An Essential Measure to Improve Oral Cavity Conditions and Symptom Management
Caterina Magnani et al.
AMERICAN JOURNAL OF HOSPICE & PALLIATIVE MEDICINE (2019)
A tool to improve the performance of multidisciplinary teams in cancer care
Lynleigh Evans et al.
BMJ OPEN QUALITY (2019)
Safety and dose modification for patients receiving niraparib
J. S. Berek et al.
ANNALS OF ONCOLOGY (2018)
Phase 1 Trial Evaluating Cisplatin, Gemcitabine, and Veliparib in 2 Patient Cohorts: Germline BRCA Mutation Carriers and Wild-Type BRCA Pancreatic Ductal Adenocarcinoma
Eileen M. O'Reilly et al.
CANCER (2018)
Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer
M. Catherine Pietanza et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
PARP10 promotes cellular proliferation and tumorigenesis by alleviating replication stress
Emily M. Schleicher et al.
NUCLEIC ACIDS RESEARCH (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Jennifer K. Litton et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
PARP-1 regulates DNA repair factor availability
Matthew J. Schiewer et al.
EMBO MOLECULAR MEDICINE (2018)
Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2
Amit M. Oza et al.
GYNECOLOGIC ONCOLOGY (2017)
Veliparib Monotherapy to Patients With BRCA Germ Line Mutation and Platinum-Resistant or Partially Platinum-Sensitive Relapse of Epithelial Ovarian Cancer A Phase I/II Study
Karina Dahl Steffensen et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2017)
NCCN Guidelines® Insights Antiemesis, Version 2.2017 Featured Updates to the NCCN Guidelines
Michael J. Berger et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2017)
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
Robert L. Coleman et al.
LANCET (2017)
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
Eric Pujade-Lauraine et al.
LANCET ONCOLOGY (2017)
Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial
Robert L. Coleman et al.
LANCET ONCOLOGY (2017)
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Mark Robson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Poly(ADP-ribosyl)ation-dependent Transient Chromatin Decondensation and Histone Displacement following Laser Microirradiation
Hilmar Strickfaden et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2016)
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
M. R. Mirza et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action
Yves Pommier et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Mechanistic Dissection of PARP1 Trapping and the Impacton In Vivo Tolerability and Efficacy of PARP Inhibitors
Todd A. Hopkins et al.
MOLECULAR CANCER RESEARCH (2015)
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
J. Mateo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib
Junko Murai et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
Jonathan Ledermann et al.
LANCET ONCOLOGY (2014)
PARP-2 and PARP-3 are selectively activated by 5' phosphorylated DNA breaks through an allosteric regulatory mechanism shared with PARP-1
Marie-France aEuro Langelier et al.
NUCLEIC ACIDS RESEARCH (2014)
Family-wide analysis of poly(ADP-ribose) polymerase activity
Sejal Vyas et al.
NATURE COMMUNICATIONS (2014)
PARP1-Driven Poly-ADP-Ribosylation Regulates BRCA1 Function in Homologous Recombination-Mediated DNA Repair
Yiduo Hu et al.
CANCER DISCOVERY (2014)
Wisconsin Ginseng (Panax quinquefolius) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind Trial, N07C2
Debra L. Barton et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2013)
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
Junko Murai et al.
CANCER RESEARCH (2012)
PARP1 promotes nucleotide excision repair through DDB2 stabilization and recruitment of ALC1
Alex Pines et al.
JOURNAL OF CELL BIOLOGY (2012)
OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Carol Aghajanian et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
The zinc-finger domains of PARP1 cooperate to recognize DNA strand breaks
Ammar A. E. Ali et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2012)
Integration of a clinical pharmacist into the hematology-oncology clinics at an academic medical center
John M. Valgus et al.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2011)
The role of oncologists in multidisciplinary cancer teams in the UK: an untapped resource for team leadership?
Benjamin Lamb et al.
JOURNAL OF EVALUATION IN CLINICAL PRACTICE (2011)
Poly(ADP-ribose) polymerase 3 (PARP3), a newcomer in cellular response to DNA damage and mitotic progression
Christian Boehler et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Enhancing adherence to capecitabine chemotherapy by means of multidisciplinary pharmaceutical care
Sven Simons et al.
SUPPORTIVE CARE IN CANCER (2011)
Impact of clinical pharmacy services on patients in an outpatient chemotherapy academic clinic
Megan McKee et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2011)
A chromatin localization screen reveals poly (ADP ribose)-regulated recruitment of the repressive polycomb and NuRD complexes to sites of DNA damage
Danny M. Chou et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Palliative Care
Michael H. Levy et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2009)
Poly(ADP-ribose) polymerase 1 accelerates single-strand break repair in concert with poly(ADP-ribose) glycohydrolase
Anna E. O. Fisher et al.
MOLECULAR AND CELLULAR BIOLOGY (2007)
Crystal structure of the catalytic fragment of murine poly(ADP-ribose) polymerase-2
AW Oliver et al.
NUCLEIC ACIDS RESEARCH (2004)
Tricyclic benzimidazoles as potent poly(ADP-ribose) polymerase-1 inhibitors
DJ Skalitzky et al.
JOURNAL OF MEDICINAL CHEMISTRY (2003)
Share Paper
